HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $35 Price Target
Benzinga Newsdesk 4 weeks ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $35 price target.
HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $35 price target.